Adalimumab biosimilar (Dong-A ST/Meiji Seika Pharma)
阿达木单抗生物类似药 (Dong-A ST/Meiji Seika Pharma)
Report date: 2022/07/19 16:22:54
Base Information
Drug NameAdalimumab biosimilar (Dong-A ST/Meiji Seika Pharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDong-A Pharmaceutical Co LtdMeiji Seika Pharmatech Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesMeiji Seika Pharmatech Co Ltd
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A